Valuation : Krystal Biotech, Inc.

Market Cap 10.64B 9.16B 8.6B 7.85B 14.74B 1,012B 14.84B 102B 39.61B 513B 39.92B 39.06B 1,700B P/E 2026 *
47.4x
P/E 2027 * 38.3x
Enterprise Value 10.64B 9.16B 8.6B 7.85B 14.74B 1,012B 14.84B 102B 39.61B 513B 39.92B 39.06B 1,700B EV / Sales 2026 *
20.8x
EV / Sales 2027 * 16.3x
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
1 day+2.25%
1 week+5.16%
Current month+5.35%
1 month+5.35%
3 months+20.55%
6 months+36.22%
Current year+45.76%
1 week 343.81
Extreme 343.81
363.82
1 month 297.02
Extreme 297.02
363.82
Current year 235.6
Extreme 235.605
382.54
1 year 136.73
Extreme 136.73
382.54
3 years 93.95
Extreme 93.95
382.54
5 years 38.86
Extreme 38.8563
382.54
10 years 8.03
Extreme 8.03
382.54
Manager TitleAgeSince
Chief Operating Officer 61 2016-04-14
Chief Executive Officer 61 2016-04-14
Investor Relations Contact - -
Director TitleAgeSince
Chairman 61 2016-04-14
Director/Board Member 61 2016-04-14
Director/Board Member 60 2016-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/14/26 Don

Director

-28,691 0.0973%
5/26/26 Sell

General Counsel

-642 0.0022%
3/4/26 Sell

Chief Executive Officer

25,000 0.0855%
Change 5-day change 1-year change 3-year change Capi.($)
+2.25%+5.16% - - 10.4B
Average +2.25%
Weighted average by Cap. +2.25%

Financials

2026 *2027 *
Net sales 513M 441M 414M 378M 710M 48.78B 715M 4.91B 1.91B 24.74B 1.92B 1.88B 81.91B 655M 564M 529M 483M 907M 62.28B 913M 6.27B 2.44B 31.59B 2.46B 2.4B 105B
Net income 237M 204M 192M 175M 329M 22.59B 331M 2.27B 884M 11.46B 891M 872M 37.93B 307M 264M 248M 226M 425M 29.17B 428M 2.94B 1.14B 14.8B 1.15B 1.13B 48.99B
Net Debt - -
Logo Krystal Biotech, Inc.
Krystal Biotech, Inc. is an integrated, commercial-stage biotechnology company. The Company is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Employees
295
Date Price Change Volume
26-08-31 US$359.36 +2.25% 222,688
26-08-28 US$351.46 -1.68% 143,509
26-08-27 US$357.46 -0.64% 181,431
26-08-26 US$359.76 +1.00% 281,025
26-08-25 US$356.19 +4.23% 205,048
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
359.36USD
Average target price
385.00USD
Spread / Average Target
+7.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. KRYS Stock